De-Risking The Supply Chain

In Q32021, ISR surveyed 124 sponsors who outsource small molecule drug substance and asked what strategies are they currently using or plan to use to de-risk their supply chain—a particularly pertinent topic in light of the events over the past few years, ranging from the COVID-19 pandemic to the conflict in the Ukraine. The data show that half of respondents (49%) do not currently have Redundant sourcing of CMOs, but plan to three years from now. One-third of respondents (38%) are currently investing in formulations with better shelf life to have accessible inventory.